Combination of AZD4573, a Selective CDK9 Inhibitor, with Other Cell Death Inducing Agents Can Overcome De Novo Venetoclax Resistance in Preclinical Hematologic Tumor Models

Cidado Justin; Boiko Scott; Proia Theresa; Woods Haley; Tavana Omid; San Martin Maryann; Tron Adriana E.; Shao Wenlin; Drew Lisa

首页> 外文期刊>Blood: The Journal of the American Society of Hematology >Combination of AZD4573, a Selective CDK9 Inhibitor, with Other Cell Death Inducing Agents Can Overcome De Novo Venetoclax Resistance in Preclinical Hematologic Tumor Models

【24h】

Combination of AZD4573, a Selective CDK9 Inhibitor, with Other Cell Death Inducing Agents Can Overcome De Novo Venetoclax Resistance in Preclinical Hematologic Tumor Models

机译：AZD4573，一种选择性CDK9抑制剂，具有其他细胞死亡诱导剂的组合可以在临床前血液肿瘤模型中克服Novo venetoclax抗性

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Blood: The Journal of the American Society of Hematology》 |2018年第novaelatreatmentappr期|共2页
作者
Cidado Justin; Boiko Scott; Proia Theresa; Woods Haley; Tavana Omid; San Martin Maryann; Tron Adriana E.; Shao Wenlin; Drew Lisa;
展开▼
作者单位

AstraZeneca Oncol IMED Biotech Unit Waltham MA USA;

AstraZeneca Waltham MA USA;

AstraZeneca Oncol IMED Biotech Unit Waltham MA USA;

AstraZeneca Waltham MA USA;

AstraZeneca Waltham MA USA;

AstraZeneca Waltham MA USA;

AstraZeneca Waltham MA USA;

AstraZeneca Oncol IMED Biotech Unit Waltham MA USA;

AstraZeneca Oncol IMED Biotech Unit Waltham MA USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类血液及淋巴系疾病;
关键词

相似文献

外文文献
专利

1. Combination of AZD4573, a Selective CDK9 Inhibitor, with Other Cell Death Inducing Agents Can Overcome De Novo Venetoclax Resistance in Preclinical Hematologic Tumor Models [J] . Cidado Justin, Boiko Scott, Proia Theresa, Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：AZD4573，一种选择性CDK9抑制剂，具有其他细胞死亡诱导剂的组合可以在临床前血液肿瘤模型中克服Novo venetoclax抗性
2. Mcl-1/CDK9 Targeting By AZD5991/AZD4573 Overcomes Intrinsic and Acquired Venetoclax Resistance in Vitro and In Vivo in PDX Model of AML through Modulation of Cell Death and Metabolic Functions [J] . Carter Bing Z., Mak Po Yee, Tao Wenjing, Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：AZD5991 / AZD4573靶向AZD5991 / AZD4573的MCL-1 / CDK9克服了在体外和在PDX模型中的内在和获得的venetoclax抗性，通过调节细胞死亡和代谢功能
3. Inhibition of CDK9 by voruciclib synergistically enhances cell death induced by the Bcl-2 selective inhibitor venetoclax in preclinical models of acute myeloid leukemia [J] . Daniel A. Luedtke, Yongwei Su, Jun Ma, Signal transduction and targeted therapy. . 2020,第1期

机译：Voruciclib的抑制CDK9协同增强了Bcl-2选择性抑制剂venetoclax在急性髓性白血病临床前模型中诱导的细胞死亡
4. Overcoming therapeutic resistance in pancreatic cancer is not a simple mix of PDT and chemotherapy: Evaluation of PDT-chemotherapy combinations in 3D tumor models [C] . Jonathan P. Celli, Ljubica Petrovic, Iqbal Massodi, Optical methods for tumor treatment and detection: mechanisms and techniques in photodynamic therapy XXII . 2013

机译：克服胰腺癌的治疗抗性不是PDT和化学疗法的简单组合：在3D肿瘤模型中评估PDT-化学疗法的组合
5. Exploitation and mechanistic validation of drug-combination strategies to overcome EGFR-inhibitor resistance in NSCLC cells [D] . Wang, Yu-Chieh. 2008

机译：克服NSCLC细胞中EGFR抑制剂耐药性的药物联合策略的开发和机理验证
6. Inhibition of CDK9 by voruciclib synergistically enhances cell death induced by the Bcl-2 selective inhibitor venetoclax in preclinical models of acute myeloid leukemia [O] . Daniel A. Luedtke, Yongwei Su, Jun Ma, 2020

机译：voruciclib抑制CDK9协同增强急性髓样白血病临床前模型中Bcl-2选择性抑制剂Venetoclax诱导的细胞死亡
7. Inhibition of CDK9 by voruciclib synergistically enhances cell death induced by the Bcl-2 selective inhibitor venetoclax in preclinical models of acute myeloid leukemia [O] . Daniel A. Luedtke, Yongwei Su, Jun Ma, 2020

机译：Voruciclib的抑制CDK9协同增强了Bcl-2选择性抑制剂venetoclax在急性髓性白血病临床前模型中诱导的细胞死亡
8. Use of Telemorace Inhibition in Combination with Anti-Cancer Drugs to Induce Cell Death in Tumor Cells [R] . Cerone, M. A. 2006

机译：使用Telemorace抑制剂与抗癌药物联合诱导肿瘤细胞死亡

Combination of AZD4573, a Selective CDK9 Inhibitor, with Other Cell Death Inducing Agents Can Overcome De Novo Venetoclax Resistance in Preclinical Hematologic Tumor Models

著录项

相似文献

相关主题

期刊订阅